Court won't stall generic Copaxone

Share this article:
Court won't stall generic Copaxone
Court won't stall generic Copaxone

Teva's fight to keep generic Copaxone off the market hit a snag Friday when the Supreme Court said it would not allow an injunction to go forward while the drugmaker waited for the appeals process to wrap. Teva's current patent claim hinges on US patent 5,800,808, also known by the shorthand ‘808, which will expire in September 2015.

Teva has been working to protect several of the MS drug's patents, of which ‘808 is just one. The impact generics may have on Teva's financial health is unclear: the company provided two scenarios for 2014 as last year wrapped that shook out with the Israel-based drugmaker pocketing between $19.8 billion and $20.8 billion in sales if generics don't strike, and between $19.3 billion and $20.3 billion in sales if they do.

Teva estimated at the time that it earns $78 million in sales for every month generic Copaxone does not exist.

Businessweek noted in March that Teva has done a fairly good job of converting Copaxone users to its patented three-times-a-week formulation. Cowen analyst Ken Cacciatore told Businessweek that watchers “may have failed to understand just how comprehensive Teva's patient outreach system has been.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...